Darapladib China PK

Model scores of the 29,894 trials active now.

Model score 4% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 7% of the time (318 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-01-04. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: hepatitisheartpharmacodynamicsfemalesuse
  Phrases that lowered it: healthyand safetyinvestigatorml ofsafety of
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 5.2% (lowers risk) · Sponsor's track record
• Sponsor's past trials: 1848 (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 318 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design
• Blinding: none (lowers risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848 NCT00743860 · started 2008 · scored riskier than 3% of active trials completed
• Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects NCT01873339 · started 2013 · scored riskier than 3% of active trials completed
• A Study to Evaluate the Effect of Antacid and Multivitamin and Mineral Tablet on the Study Drug GSK1349572 NCT00858455 · started 2009 · scored riskier than 1% of active trials completed
• The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 100mg Compared With Compressed Tablet 100 mg NCT02064465 · started 2014 · scored riskier than 2% of active trials completed
• Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers NCT05162131 · started 2021 · scored riskier than 4% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.